Who are ER-niacin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nicotinic acid (niacin), Omega-3 Supplementation, fatty acids, omega-3, Niacin/ Laropiprant, omega-3-fatty acids (Omegaven), Niacin plus laropiprant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/er-niacin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ER-niacin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ER-niacin (ER-niacin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipid-modifying agent; B-vitamin. Area: Cardiovascular.

phase 3 Lipid-modifying agent; B-vitamin DGAT2; GPR109A (hydroxycarboxylic acid receptor 2) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ER-niacin (ER-niacin) — Merck Sharp & Dohme LLC. ER-niacin is an extended-release formulation of niacin (vitamin B3) that raises HDL cholesterol and lowers triglycerides and LDL cholesterol.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ER-niacin TARGET	ER-niacin	Merck Sharp & Dohme LLC	phase 3	Lipid-modifying agent; B-vitamin	DGAT2; GPR109A (hydroxycarboxylic acid receptor 2)
Nicotinic acid (niacin)	Nicotinic acid (niacin)	Charite University, Berlin, Germany	marketed	Lipid-modifying agent; B vitamin	GPR109A (HM74A receptor)
Omega-3 Supplementation	Omega-3 Supplementation	Università degli Studi di Brescia	marketed	Dietary supplement / Lipid-modifying agent	GPR120, GPR40, PPAR-γ, NF-κB signaling pathway
fatty acids, omega-3	fatty acids, omega-3	National Heart, Lung, and Blood Institute (NHLBI)	marketed	Lipid-modifying agent
Niacin/ Laropiprant	Niacin/ Laropiprant	Ludwig-Maximilians - University of Munich	marketed	Lipid-modifying agent; prostaglandin D2 receptor antagonist	DGAT2 (niacin); DP1 prostaglandin receptor (laropiprant)
omega-3-fatty acids (Omegaven)	omega-3-fatty acids (Omegaven)	Li Shin Hospital	marketed	Lipid-modifying agent; anti-inflammatory
Niacin plus laropiprant	Niacin plus laropiprant	Institut Investigacio Sanitaria Pere Virgili	marketed	Lipid-modifying agent combination	DP1 receptor (laropiprant component); niacin acts on GPR109A and other pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipid-modifying agent; B-vitamin class)

Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ER-niacin — Competitive Intelligence Brief. https://druglandscape.com/ci/er-niacin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing